Abstract
An increase in the expression of epidermal growth factor receptors (EGFR) is involved in the stimulation of tumor development. EGFR inhibitors have shown efficacy in the treatment of neoplasms of the head, neck, colon and lung. EGFR when inhibited can cause cutaneous reactions in more than 50% of the patients. They are usually reversible, but when severe, limit the use of the drug. Papulopustulars lesions in the face and upper torso are the most common, as well as xerosis, hair and nail changes. There is a direct relationship between the degree of cutaneous toxicity and the antitumoral response. An adequate dermatologic approach is necessary for an effective therapy against cancer. ©2009 by Anais Brasileiros de Dermatologia.
Author supplied keywords
Cite
CITATION STYLE
Rodarte, C. M., Abdallah, O. A., Barbosa, N. F., Koch, L. D. O., & Resende, U. M. (2009). Reações cutâneas secundárias ao uso dos inibidores do receptor de fator de crescimento epidérmico: Relato de dois casos. Anais Brasileiros de Dermatologia, 84(6), 667–670. https://doi.org/10.1590/S0365-05962009000600015
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.